In June last year, it landed at Changchun Bcht Biotechnology Co(688276) (688276, ” Changchun Bcht Biotechnology Co(688276) “) on the science and Innovation Board of Shanghai Stock Exchange. The “2021 annual performance express” released today showed that the revenue and net profit showed a “double decline” during the reporting period.
revenue and net profit attributable to parent decreased
The announcement shows that during the reporting period, the total operating revenue of the company was 1202026600 yuan, 1441358100 yuan in the same period of last year, a decrease of 239331500 yuan or 16.60%; The net profit attributable to the parent company was 243553400 yuan, 418234800 yuan in the same period of last year, a decrease of 174681400 yuan or 41.77%; Non net profit deducted was 233619300 yuan, 401883800 yuan in the same period of last year, a decrease of 168.2645 million yuan or 41.87%.
With regard to the large range of changes in relevant financial data, Changchun Bcht Biotechnology Co(688276) said that due to the covid-19 epidemic and the centralized vaccination of covid-19 vaccine, especially in the second half of 2021, based on the continuous vaccination of people over the age of 18, covid-19 virus vaccination for people aged 3-17 weeks has been launched all over the country, As a result, the promotion and vaccination of the company’s main products varicella live attenuated vaccine and freeze-dried nasal spray influenza live attenuated vaccine have been greatly impacted.
The more prominent impact is the promotion and vaccination of influenza vaccine. The vaccination of influenza vaccine has a strong seasonality, and the applicable population of the company’s Lyophilized nasal spray live attenuated influenza vaccine is 3-17 years old, which highly coincides with the key population vaccinated with covid-19 vaccine in the same period, resulting in a great impact on the vaccine promotion in the whole influenza season.
In the past two years, vaccine products similar to the company have been approved for listing one after another. There are many influenza vaccine products in the market, and the market competition in the industry is increasing, which has a certain impact on the sales of products. The company’s operating revenue fell 16.60% due to dual reasons.
The reporter noted that according to the record of Changchun Bcht Biotechnology Co(688276) investor relations activities released on January 7, 2022, the production capacity of varicella vaccine stock solution of the company is 15 million people / year. Due to the current capacity limit of freeze-drying workshop, the production capacity of finished products is limited to 10 million people / year. At present, the construction of a new freeze-drying workshop has been completed, and the production capacity can reach 15 million people / year next year. The raw liquid workshop is under construction, and the production capacity can be increased by 20 million people / year after it is put into operation.
The production capacity of nasal spray influenza vaccine freeze-drying workshop is 14.4 million people / year, which limits the production capacity. After the liquid dosage form is put into operation, the production capacity will continue to increase and gradually release; More than 3.9 million copies of freeze-dried nasal spray influenza vaccine were issued in batches this year.
As the company’s freeze-dried live attenuated influenza vaccine is a seasonal sales product with a validity period of 10 months, affected by covid-19 epidemic situation and covid-19 vaccine centralized vaccination and other factors, Changchun Bcht Biotechnology Co(688276) decided to withdraw asset impairment reserves for freeze-dried live attenuated influenza vaccine and expired materials that are expected to fail to be sold, totaling 87.6866 million yuan.
expensed R & D expenditure increased by 67.9% year-on-year
In terms of R & D, Changchun Bcht Biotechnology Co(688276) said that it would continue to increase R & D investment and continue to promote the R & D of products under development such as all human anti rabies monoclonal antibodies. In 2021, the company’s expensed R & D expenditure was 1567602 million yuan, an increase of 63.3954 million yuan over the same period last year.
According to the record of Changchun Bcht Biotechnology Co(688276) investor relations activities released on January 7, 2022 and February 17, 2022, the varieties under research include herpes zoster vaccine, nasal spray influenza vaccine (liquid preparation), DPT component vaccine, whole human anti rabies monoclonal antibody, whole human anti tetanus toxin monoclonal antibody, diploid rabies, adjuvant influenza Alzheimer’s disease vaccine, etc.
Among them, nasal spray influenza vaccine (liquid preparation) has obtained clinical approval in early 2021 and is undergoing clinical research; Herpes zoster vaccine is preparing for application and production, which is the two products that have made rapid progress at present.
However, Changchun Bcht Biotechnology Co(688276) also admitted that the next step of herpes zoster vaccine still needs to carry out CDE expert exchange meeting. After the exchange meeting, you can formally apply for NDA and apply for rapid approval. If it is included in the rapid review, the review time limit is 130 working days, but the approval process and time are uncertain.
By the end of the reporting period, the total assets of the company were 4174.6352 million yuan, 2467.5218 million yuan at the beginning of the period, an increase of 1707.1134 million yuan, an increase of 69.18%; The owner’s equity attributable to the parent company was 3417583200 yuan, 1779956100 yuan at the beginning of the period, an increase of 1637627100 yuan, an increase of 92.00%, mainly due to the increase of funds raised by the company’s public offering of shares in Shanghai stock exchange during the reporting period.
According to the data, Changchun Bcht Biotechnology Co(688276) was established on March 4, 2004. It is a high-tech enterprise integrating new drug R & D, production and sales funded by Changchun High And New Technology Industries (Group) Inc(000661) . It landed on the science and Innovation Board of Shanghai Stock Exchange on June 25, 2021. Ma Ji is the legal representative and chairman and Changchun High And New Technology Industries (Group) Inc(000661) is the major shareholder holding 41.54%.
